Anakinra: Interleukin-1 receptor antagonist therapy for rheumatoid arthritis

Garces K
Record ID 32001000941
English, French
Authors' objectives:

To summarise the available evidence on the use of anakinra for rheumatoid arthritis (RA).

Authors' recomendations: - Anakinra is an interleukin-1 receptor antagonist (IL-1ra), which blocks interleukin-1 (IL-1), a protein involved in the inflammation and the joint destruction associated with rheumatoid arthritis (RA). - The manufacturer's submission for drug approval is currently under review by Health Canada and the FDA. - In randomized controlled trials, patients with severe RA were treated with anakinra. Significant improvement was demonstrated in several clinical, radiologic and health-related quality of life measures in patients treated with anakinra versus placebo. - Minimal adverse effects, mainly injection site reactions, were reported.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Receptors, Interleukin-1
  • Arthritis, Rheumatoid
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.